Knowledge base · research

PEG-MGF — mechano growth factor in regeneration models

PEG-MGF (Pegylated Mechano Growth Factor) is a pegylated variant of the so-called mechano growth factor — a peptide that is an alternative splice variant of the IGF-1 gene (described in humans as the IGF-1Ec isoform). Unlike the circulating, hepatic form of IGF-1, MGF is produced locally in muscle tissue in response to mechanical load and micro-damage to the fibres. It thus represents a separate, mechanically induced branch of the growth hormone / IGF-1 axis (GH/IGF).

Native MGF is a very unstable molecule — its window of activity in biological systems is short. Pegylation, i.e. the attachment of a polyethylene glycol (PEG) chain, is a standard modification used in peptide chemistry that increases stability and prolongs the presence of the molecule in a research model. It is precisely this feature that makes PEG-MGF a convenient tool for preclinical research into local tissue repair processes.

Mechanism in brief

The key element of MGF is a unique C-terminal fragment (the so-called E domain), which differs from classic IGF-1 and gives the molecule a distinct activity profile. In the preclinical literature two levels of activity are considered: the part shared with the IGF-1 axis (signalling via the IGF-1R receptor — the "lock and key" model, where the peptide fits a specific receptor) and the action of the E-domain peptide itself, which in some systems has been described as independent of the IGF-1R receptor.

The main pathway under investigation is a local, mechanically induced regenerative response: mechanical signal → expression of the MGF variant → activation of nearby muscle precursor cells. Pegylation does not change the "address" of the molecule — it acts as a shield that extends the window in which the peptide remains available for observation in the model.

What is the subject of research

  • Activation of satellite cells — in myoblast cultures in vitro and in animal models, the ability of MGF to stimulate satellite cells (muscle stem cells) to exit quiescence and proliferate has been studied. The pathway is linked to IGF-1R signalling and to cascades dependent on kinases responsible for the cell cycle.
  • Repair processes after muscle tissue damage — in animal models with induced fibre damage, the role of the mechanically induced branch of the GH/IGF axis in the early stages of regeneration was analysed. The object of observation is the dynamics of precursor cell recruitment, not any effect in humans.
  • Myoblast differentiation — in vitro studies on cell lines (e.g. myoblasts) concern the influence of the E domain on the balance between proliferation and differentiation of cells, as an element of modelling the biology of muscle regeneration.
  • Neuronal survival models — beyond muscle tissue, the MGF E-domain peptide has been studied in models of neuronal injury and ischaemia in the context of cell survival pathways. This is a separate, early direction of preclinical research.

Each of these areas remains at the level of model research and requires further study. They do not describe any action in humans.

Origin and historical context

The concept of the mechano growth factor derives from British work on muscle physiology from the late 1990s, largely associated with the team of Prof. Geoffrey Goldspink (the London academic community). It was observed at that time that, under a mechanical stimulus, muscle expresses an alternative transcript variant of IGF-1 with a different C-terminus — named precisely mechano growth factor. Subsequent work by academic laboratories focused on characterising the E domain and its role in satellite cells, and modified versions, including pegylated ones, emerged as tools to increase peptide stability for the purposes of experiments.

Research specification

PEG-MGF is offered in the form of a lyophilisate (a powder for reconstitution under laboratory conditions). The quality standard is purity determination by the HPLC method — an analytical parameter describing the homogeneity of the preparation, without any promises as to biological action. Detailed physicochemical data, including molecular weight, CAS number and storage conditions, are provided in the product documentation and safety data sheets (COA/SDS). Each batch should be verified against the accompanying certificate of analysis.

Level of evidence

Honestly about the limits of the data: the available knowledge about PEG-MGF is based primarily on in vitro studies (myoblast cultures, cell lines) and animal models. Data from human studies are limited or absent, and the modifications themselves (pegylation) additionally change the profile of the molecule relative to native MGF, which makes it difficult to transfer conclusions directly. None of the described mechanisms constitutes a confirmed clinical effect. This area remains the subject of early research and requires further verification.

For research purposes only. Not for human or animal consumption. This product is not a medicine, a dietary supplement or a medical device.

Frequently asked questions

How does PEG-MGF differ from ordinary MGF?
PEG-MGF is a variant of the mechano growth factor with an attached polyethylene glycol chain (pegylation). The peptide sequence itself remains the same, but the PEG modification increases stability and extends the window in which the molecule remains available for observation in a research model. Native MGF is very unstable, which makes it difficult to use in experiments.
What is the relationship between MGF and IGF-1?
MGF is a splice variant of the IGF-1 gene — described in humans as the IGF-1Ec isoform. It differs by a unique C-terminal fragment (the E domain). Unlike the circulating form of IGF-1, MGF is produced locally in muscle in response to a mechanical stimulus, which is why it is sometimes described as a mechanically induced branch of the GH/IGF axis.
What exactly is the subject of research on PEG-MGF?
In in vitro and animal models, the activation of satellite cells, muscle tissue repair processes after damage, myoblast differentiation and survival pathways in neuronal models have been studied. All of these areas concern model systems and require further study — they do not describe any action in humans.
In what form is PEG-MGF available and how is quality verified?
The standard is a lyophilisate (a powder for reconstitution under laboratory conditions) with purity determination by the HPLC method as an analytical parameter. Physicochemical data, molecular weight, CAS and storage conditions are provided in the safety data sheets (COA/SDS) available in the documentation section.
Is there any data from human studies?
The available knowledge is based mainly on in vitro studies and animal models. Data from human studies are limited or absent, and pegylation additionally changes the profile of the molecule relative to native MGF. None of the mechanisms constitutes a confirmed clinical effect.
For research purposes only. Not for human or animal consumption. This content is scientific and informational (mechanisms and research models) and is not medical advice or usage guidance.
View product → Build a research stack → Reconstitution calculator →

Related articles

AOD-9604 — fragment 176-191 and metabolic pathways in models AOD-9604: a modified 176-191 fragment of hGH as a tool for studying lipid metabolism pathways in animal models Read → CJC-1295 — a GHRH analog and GH axis signaling in research CJC-1295 is a GHRH analog studied in preclinical models for GH axis signaling and pulsatile pituitary stimulat Read → HGH Fragment 176-191 — C-terminal GH fragment in metabolic research HGH Fragment 176-191 — C-terminal fragment of growth hormone studied in animal models for lipid metabolism pat Read → Ipamorelin — a selective GH secretagogue in the research literature Ipamorelin — a pentapeptide and selective growth hormone secretagogue (ghrelin receptor agonist). Mechanism, a Read →
Research newsletter
New research write-ups by email
No noise. Mechanisms, models and quality documentation — when something worthwhile appears.